Generic Posimir Availability
Last updated on Apr 10, 2024.
Posimir is a brand name of bupivacaine, approved by the FDA in the following formulation(s):
POSIMIR (bupivacaine - solution, extended release;infiltration)
-
Manufacturer: INNOCOLL
Approval date: February 1, 2021
Strength(s): 660MG/5ML (132MG/ML) [RLD]
Has a generic version of Posimir been approved?
No. There is currently no therapeutically equivalent version of Posimir available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Posimir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 11,400,019
Patent expiration dates:
- January 12, 2041✓
- January 12, 2041
-
Patent 11,771,624
Patent expiration dates:
- January 12, 2041✓
- January 12, 2041
-
Controlled delivery system
Patent 8,153,149
Issued: April 10, 2012
Inventor(s): Verity A. Neil
Assignee(s): Durect CorporationThe present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided.
Patent expiration dates:
- September 15, 2025✓
- September 15, 2025
-
Controlled delivery system
Patent 8,153,661
Issued: April 10, 2012
Inventor(s): Verity A. Neil
Assignee(s): Durect CorporationThe present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided.
Patent expiration dates:
- September 15, 2025✓
- September 15, 2025
-
Controlled delivery system
Patent 8,753,665
Issued: June 17, 2014
Inventor(s): Verity A. Neil
Assignee(s): Durect CorporationThe present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided. Preferably the composition contains bupivacaine and a sugar ester such as saib.
Patent expiration dates:
- September 15, 2025✓✓
- September 15, 2025
-
Controlled delivery system
Patent 8,846,072
Issued: September 30, 2014
Inventor(s): Verity A. Neil
Assignee(s): Durect CorporationThe present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided.
Patent expiration dates:
- September 15, 2025✓✓
- September 15, 2025
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- February 1, 2024 - NEW PRODUCT
More about Posimir (bupivacaine)
- Check interactions
- Compare alternatives
- Latest FDA alerts (6)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: local injectable anesthetics
- Breastfeeding
Patient resources
Other brands
Marcaine, Sensorcaine, Sensorcaine-MPF, Marcaine Spinal, ... +2 more
Professional resources
Other brands
Marcaine, Sensorcaine-MPF, Marcaine Spinal, Xaracoll
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.